This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection . Oral presentationO125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients1 CRC, Uganda, Uganda 2 MRC Clinical Trials Unit, London, UK 3 Infectious Diseases Institute, Mulago, Uganda 4 Joint Clinical Trials Unit, London, UK 5 Joint Clinical Research Centre, Kampala, Uganda 6 MRC/UVRI Research Unit on AIDS, Entebbe, Uganda 7 University of Zimbabwe, Harare, Zimbabwe 8 Imperial College, London, UK 9 Liverpool University, Liverpool, UK
from Ninth International Congress on Drug Therapy in HIV Infection Journal of the International AIDS Society 2008, 11(Suppl 1):O10doi:10.1186/1758-2652-11-S1-O10
First paragraph (this article has no abstract)With NNRTI, the recommended dose of lopinavir/r (LPV/r) is 4 capsules (533/133 mg) BD. With LPV/r tablets, the closest doses are 2 tablets (400/100 mg) BD or 3 tablets [tabs] (600/150 mg) BD. Improved bioavailability of the tablet suggests that 2 tabs BD should be sufficient, but PK data are few and generally from Caucasians. |




on Google Scholar







corresponding author email